Philogen

CompanyItaly

Philogen develops one asset, in phase 3 (F16IL2 in soft tissue sarcoma). Mostly protein or enzyme acting on inflammation, IL2RA and IL2RB; based in Italy.

Assets
1
Furthest
Phase 3
Trials
5
Signals
0

Pipeline

1

  • F16IL2

    Antibody-cytokine fusion protein targeting the A1 domain of tenascin-C coupled with interleukin-2.

    Phase 3Protein or enzymeInflammationIL2RAsoft tissue sarcomaleiomyosarcoma (Phase 2)

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms3
  • Trials5
  • Similar companies6

Updated 7 Oct 2026 · 11 sources

Intelligence